BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria
BetterLife Pharma announced that its researchers will present preclinical data on BETR-001 at the 2024 FENS conference in Vienna. BETR-001 is a non-hallucinogenic LSD derivative targeting mental health disorders. The study, conducted by Drs. Vern Lewis and Argel Aguilar-Valles from Carleton University, reveals that BETR-001 activates key signaling pathways linked to neuroplasticity and neurotransmission, which are critical in treating depression and anxiety. Additionally, BETR-001 shows potential in addressing neurodegeneration and addiction. CEO Dr. Ahmad Doroudian expressed optimism about these findings, indicating broad therapeutic applications for BETR-001.
- Presentation of BETR-001 preclinical data at a prestigious conference could enhance company visibility and credibility.
- Preclinical data indicate BETR-001 activates key signaling pathways involved in depression and anxiety, supporting its therapeutic potential in mental health disorders.
- Discovery of potential applications of BETR-001 in treating neurodegeneration and addiction expands market opportunities.
- As the data presented are preclinical, they require further validation through clinical trials, posing a risk of future unverified efficacy.
VANCOUVER, British Columbia, June 26, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its scientific collaborators, Drs. Vern Lewis and Argel Aguilar-Valles from Carleton University’s Department of Neuroscience (Ottawa, Canada), will present data from a study investigating the mechanisms of BETR-001 (2-bromo-LSD) at the upcoming FENS conference on June 25-29 in Vienna, Austria. BETR-001 is a non-hallucinogenic derivative of LSD, proprietary to BetterLife (patent pending). The study is titled “Cortical transcriptomic effects of the non-hallucinogenic 2-Bromo-LSD”.
Dr. Lewis will present preclinical gene sequencing data showing that BETR-001 activates several key signalling pathways involved in neuroplasticity and neurotransmission (related to depression and anxiety) as well as many gene targets involved in axon guidance and addiction.
Dr. Ahmad Doroudian, CEO of BetterLife, commented, “We are very excited about these recent preclinical findings that show BETR-001 activates key signaling pathways involved in pathology of depressive disorders, in line with previous data from depression and anxiety preclinical models. Furthermore, these data indicate that BETR-001 may have therapeutic potential beyond mood disorders and be effective in treating conditions such as neurodegeneration and addiction disorders.”
About BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.
BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be potentially self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.
BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.
For further information, please visit BetterLife Pharma.
BetterLife Pharma Inc. Contact Information
David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928
Cautionary Note Regarding Forward-Looking Statements
No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
FAQ
What is BETR-001?
When and where will the BETR-001 data be presented?
What were the key findings about BETR-001?
Who conducted the BETR-001 study?
What is the market potential of BETR-001?
